Nocebo in headaches: implications for clinical practice and trial design

Area of Science:

• Neuroscience
• Clinical Psychology
• Pharmacology

Background:

• The nocebo effect describes adverse events from inert treatments, often driven by patient fear and negative expectations.
• This phenomenon mirrors the placebo effect but results in harmful outcomes.
• Nocebo responses are particularly relevant in pain conditions and clinical trial research.

Purpose of the Study:

• To investigate the prevalence and impact of the nocebo effect in randomized controlled trials for primary headache prevention.
• To analyze how negative expectations influence patient-reported adverse events in placebo groups.
• To discuss the implications of the nocebo effect on trial design and clinical practice.

Main Methods:

• Systematic meta-analyses were conducted on trials for migraine and tension-type headache prevention.
• Data on adverse events in placebo groups were analyzed.
• The study examined the correlation between expected adverse events and those reported by patients receiving placebos.

Main Results:

• Approximately 1 in 20 patients (5%) in placebo groups withdrew from treatment due to adverse effects.
• Adverse events reported in placebo groups were consistent with those expected from the active medication.
• Pretrial suggestions were confirmed as a significant inducer of nocebo effects in patients.

Conclusions:

• The nocebo effect significantly impacts randomized controlled trials by reducing the study population (by ~10%) and potentially limiting treatment outcome assessments.
• Understanding and mitigating the nocebo effect is crucial for accurate clinical trial interpretation.
• Strategies to address patient expectations are needed for both clinical practice and trial design.